Recombinant ArgF PLGA nanoparticles enhances BCG induced immune responses against Mycobacterium bovis infection-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Recombinant ArgF PLGA nanoparticles enhances BCG induced immune responses against Mycobacterium bovis infection

Published:2021-05 Issue: Volume:137 Page:111341
ISSN:0753-3322
Container-title:Biomedicine & Pharmacotherapy
language:en
Short-container-title:Biomedicine & Pharmacotherapy

Author:

Ni Jiamin,Liu Yiduo,Hussain Tariq,Li Miaoxuan,Liang Zhengmin,Liu Tianlong,Zhou Xiangmei

Funder

National Natural Science Foundation of China

Publisher

Elsevier BV

Subject

Pharmacology,General Medicine

Reference41 articles.

1. Recombinant live vaccine candidates against tuberculosis;Kaufmann;Curr. Opin. Biotechnol.,2012

2. Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials;Mangtani;Clin. Infect. Dis.,2014

3. WHO, Global Tuberculosis Report 2019, 2019. 〈https://www.who.int/tb/publications/global_report/zh/〉. (Accessed 23 June 2020).

4. Therapeutic aerosol bioengineering of targeted, inhalable microparticle formulations to treat Mycobacterium tuberculosis (MTb);Lawlor;J. Mater. Sci. Mater. Med.,2012

5. Inhaled drug treatment for tuberculosis: past progress and future prospects;Hickey;J. Control Release,2016

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Selenium nanoparticles enhance mucosal immunity against Mycobacterium bovis infection;International Immunopharmacology;2024-08

2. Phosvitin-based hydrogels prepared in AmimCl under magnetic field treatment: Structural characteristics, biological functions, and application in skin wound healing;International Journal of Biological Macromolecules;2024-02

3. In vitroandin silicoevaluation of the design of nano-phyto-drug candidate for oral use againstStaphylococcus aureus;PeerJ;2023-06-08

4. Tuberculosis Vaccines for Cattle;CABI Reviews;2023-03-17

5. Inhalable Polymeric Micro and Nano-immunoadjuvants for Developing Therapeutic Vaccines in the Treatment of Non-small Cell Lung Cancer;Current Pharmaceutical Design;2022-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3